Showing 21 - 40 results of 215 for search '"hemostasis"', query time: 0.12s Refine Results
  1. 21
  2. 22
  3. 23

    Clinical role of endothelial dysfunction and hemostasis gene allelic variants in hepatitis C virus-associated cryoglobulinemia by M. V. Sokolova, Ye. Ye. Starostina, T. N. Krasnova, L. M. Samokhodskaya, T. P. Rozina, V. G. Avdeyev, M. G. Artemova, Ye. B. Yarovaya, N. A. Mukhin

    Published 2018-08-01
    “…To estimate the effect of carriage of endothelial dysfunction and hemostasis gene allelic variants on development of cryoglobulinemic vasculitis (CryoVas) and its clinical symptoms in patients with chronic hepatitis C (CHC). …”
    Get full text
    Article
  4. 24

    Timing of Rebleeding in High-Risk Peptic Ulcer Bleeding after Successful Hemostasis: A Systematic Review by Sara El Ouali, Alan N Barkun, Myriam Martel, Davide Maggio

    Published 2014-01-01
    “…BACKGROUND: Peptic ulcer rebleeding (PUR) usually occurs within three days following endoscopic hemostasis. However, recent data have increasingly suggested delayed rebleeding.…”
    Get full text
    Article
  5. 25

    Therapy with Interleukin-22 Alleviates Hepatic Injury and Hemostasis Dysregulation in Rat Model of Acute Liver Failure by Tariq Helal Ashour

    Published 2014-01-01
    “…Taken together, therapy with IL-22 can represent a promising therapeutic tool against liver injury and its associated hemostasis disturbances.…”
    Get full text
    Article
  6. 26
  7. 27
  8. 28

    Implementation of a Cost and Variation Reduction Program for Hemostasis Products at a Large Academic Medical Center: A Multi-Stakeholder Perspective by Shah T, Brethauer S, Danker III WA, Doshi I, O'Hara M, Silber A, Vasileff WK

    Published 2025-01-01
    “…Thus, we sought to evaluate hospital stakeholder satisfaction with conversion to a sole supplier for hemostasis products, in addition to economic and clinical impacts, to help develop best practices for implementation.Methods: This cross-sectional study assessed satisfaction with converting to a sole supplier for hemostasis products at a large US academic medical center using qualitative interviews and quantitative surveys with clinical and non-clinical stakeholders, on the decision-making process, conversion, and vendor-supported hemostasis optimization program (HOP) post-implementation (February 2022–May 2022). …”
    Get full text
    Article
  9. 29
  10. 30
  11. 31
  12. 32
  13. 33
  14. 34

    Green biosynthetic silver nanoparticles from Ageratum conyzoides as multifunctional hemostatic agents: Combining hemostasis, antibacterial, and anti-inflammatory properties for effective wound healing by Yang Li, Yinfeng Tan, Huange Zhao, Shiting Chen, Azadeh Nilghaz, Rong Cao, Songlin Zhou

    Published 2025-04-01
    “…Widespread interest in new hemostatic agents arises from the challenge of simultaneously satisfying the requirements of hemostatic, antibacterial, and anti-inflammatory properties while also considering the associated economic costs. An ideal hemostasis material should facilitate rapid hemostasis, intervene against infection, promote wound healing, and be cost-effective and easy to prepare. …”
    Get full text
    Article
  15. 35
  16. 36
  17. 37
  18. 38
  19. 39
  20. 40